Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.60 |
| ▸ | HPGD | P15428 | 4/20 | 0.60 |
| ▸ | MEN1 | O00255 | 3/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.60 |
| ▸ | TP53 | P04637 | 2/20 | 0.60 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.60 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.60 |
| ▸ | NPC1 | O15118 | 2/20 | 0.60 |
| ▸ | RAB9A | P51151 | 2/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.60 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.60 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.60 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.60 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.60 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.60 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.60 |
| ▸ | HPGDS | O60760 | 1/20 | 0.60 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.60 |
| ▸ | PKM | P14618 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL111127 | 0.88 | ALDH1A1 (0.73) | ALDH1A1HPGDMEN1KMT2AKDM4E | |
| SCHEMBL15417359 | 0.88 | ALDH1A1 (0.60) | ALDH1A1HPGDMEN1KMT2AKDM4E | |
| SCHEMBL15417358 | 0.86 | ALDH1A1 (0.70) | ALDH1A1HPGDMEN1KMT2AKDM4E | |
| SCHEMBL15417392 | 0.85 | ALDH1A1 (0.69) | ALDH1A1HPGDMEN1KMT2AKDM4E | |
| SCHEMBL30263637 | 0.84 | MEN1 (0.82) | ALDH1A1HPGDMEN1KMT2AKDM4E | |
| SCHEMBL29008942 | 0.84 | MEN1 (0.82) | ALDH1A1HPGDMEN1KMT2AKDM4E | |
| SCHEMBL15417362 | 0.84 | MEN1 (0.82) | ALDH1A1HPGDMEN1KMT2AKDM4E | |
| SCHEMBL30377355 | 0.84 | MEN1 (0.82) | ALDH1A1HPGDMEN1KMT2AKDM4E | |
| SCHEMBL110024 | 0.84 | TRPA1 (0.58) | ALDH1A1HPGDMEN1KMT2AKDM4E | |
| SCHEMBL21025307 | 0.80 | MMP1 (0.59) | ALDH1A1HPGDMEN1KMT2AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180117050-A1 | METHODS OF TREATING EYE DISEASES ASSOCIATED WITH INFLAMMATION AND VASCULAR PROLIFERATION | OCCURX PTY LTD (AU) | 2018-05-03 | — | — | US | disclosed |
| US-20180117049-A1 | METHODS OF TREATING EYE DISEASES ASSOCIATED WITH INFLAMMATION AND VASCULAR PROLIFERATION | OCCURX PTY LTD (AU) | 2018-05-03 | — | — | US | disclosed |
| US-20180117051-A1 | METHODS OF TREATING EYE DISEASES ASSOCIATED WITH INFLAMMATION AND VASCULAR PROLIFERATION | OCCURX PTY LTD (AU) | 2018-05-03 | — | — | US | disclosed |
| US-9839640-B2 | Methods of treating eye diseases associated with inflammation and vascular proliferation | OCCURX PTY LTD (AU) | 2017-12-12 | — | — | US | disclosed |
| US-8624056-B2 | Halogenated analogues of anti-fibrotic agents | FIBROTECH THERAPEUTICS PTY LTD | 2014-01-07 | — | — | US | disclosed |
| US-20130310386-A1 | METHODS OF TREATING EYE DISEASES ASSOCIATED WITH INFLAMMATION AND VASCULAR PROLIFERATION | FIBROTECH THERAPEUTICS PTY LTD (AU) | 2013-11-21 | — | — | US | disclosed |
| US-20120059188-A9 | HALOGENATED ANALOGUES OF ANTI-FIBROTIC AGENTS | THE UNIVERSITY OF MELBOURNE (AU) | 2012-03-08 | — | — | US | disclosed |
| US-20110021815-A1 | HALOGENATED ANALOGUES OF ANTI-FIBROTIC AGENTS | FIBROTECH THERAPEUTICS PTY LTD (AU) | 2011-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180117049-A1 | METHODS OF TREATING EYE DISEASES ASSOCIATED WITH INFLAMMATION AND VASCULAR PROLIFERATION | VCAM1, PTGIS, NFKBIA | ALDH1A1 668/4885HPGD 870/4885MEN1 3939/4885 |
| US-20130310386-A1 | METHODS OF TREATING EYE DISEASES ASSOCIATED WITH INFLAMMATION AND VASCULAR PROLIFERATION | VCAM1, PTGIS, NFKBIA | ALDH1A1 668/4885HPGD 870/4885MEN1 3939/4885 |
| US-20120059188-A9 | HALOGENATED ANALOGUES OF ANTI-FIBROTIC AGENTS | MMP1, FIBP, HDGF | ALDH1A1 242/4885HPGD 1175/4885MEN1 3475/4885 |
| US-20180117050-A1 | METHODS OF TREATING EYE DISEASES ASSOCIATED WITH INFLAMMATION AND VASCULAR PROLIFERATION | VCAM1, PTGIS, NFKBIA | ALDH1A1 668/4885HPGD 870/4885MEN1 3939/4885 |
| US-20180117051-A1 | METHODS OF TREATING EYE DISEASES ASSOCIATED WITH INFLAMMATION AND VASCULAR PROLIFERATION | VCAM1, PTGIS, NFKBIA | ALDH1A1 668/4885HPGD 870/4885MEN1 3939/4885 |
| US-20110021815-A1 | HALOGENATED ANALOGUES OF ANTI-FIBROTIC AGENTS | MMP1, FIBP, HDGF | ALDH1A1 242/4885HPGD 1175/4885MEN1 3475/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.